Company research
Gossamer Bio, Inc.
CIK 1728117Updated Sep 24, 2026
SecurityGOSS · NASDAQ · equity
GOSS price & chart
Loading TradingView…
NASDAQ:GOSS on TradingView ↗About the company
Gossamer Bio is a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.
In the news
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm ↗
GOSS DEADLINE NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class Action – GOSS ↗
GOSS DEADLINE NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class Action – GOSS ↗
Recent filings
Other Events
Items 8.01
DEF 14A filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Other Events
Items 3.03, 5.03, 8.01, 9.01
Other Events
Items 8.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 172,249,000Source | 315,292,000Source | 311,916,000Source | 272,450,000Source |
| Property, Plant and Equipment, NetUSD | 64,000Source | 10,000Source | 1,648,000Source | 3,981,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 37,732,000Source | 46,074,000Source | 32,109,000Source | 111,973,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 12,227,000Source | 5,338,000Source | — | — |
| Assets, CurrentUSD | 167,644,000Source | 309,888,000Source | 306,519,000Source | 261,880,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 18,485,000Source | 10,032,000Source | 10,094,000Source | 6,202,000Source |
| Operating Lease, Right-of-Use AssetUSD | 4,133,000Source | 5,111,000Source | 3,131,000Source | 5,909,000Source |
| Other Assets, NoncurrentUSD | 408,000Source | 283,000Source | 618,000Source | 680,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 295,009,000Source | 285,800,000Source | 249,147,000Source | 260,373,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 24,000Source | 23,000Source | 23,000Source | 10,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,438,938,000Source | -1,268,568,000Source | -1,212,040,000Source | -1,032,223,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -5,149,000Source | 1,189,000Source | -350,000Source | -574,000Source |
| Stockholders' Equity Attributable to ParentUSD | -122,760,000Source | 29,492,000Source | 62,769,000Source | 12,077,000Source |
| Additional Paid in Capital, Common StockUSD | 1,321,303,000Source | 1,296,848,000Source | 1,275,136,000Source | 1,044,864,000Source |
| Liabilities and EquityUSD | 172,249,000Source | 315,292,000Source | 311,916,000Source | 272,450,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 63,435,000Source | 45,010,000Source | 51,598,000Source | 49,230,000Source |
| Operating Lease, Liability, CurrentUSD | 938,000Source | 961,000Source | 3,302,000Source | 2,983,000Source |
| Accounts Payable, CurrentUSD | 5,959,000Source | 2,319,000Source | 5,526,000Source | 1,459,000Source |
| Operating Lease, Liability, NoncurrentUSD | 3,460,000Source | 4,398,000Source | 144,000Source | 3,446,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 15,827,000Source | 15,186,000Source | 26,680,000Source | 20,532,000Source |
| Long-term Debt, Current MaturitiesUSD | — | 0Source | 11,613,000Source | 11,613,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 0Source | 814,000Source | 11,988,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -170,370,000Source | -56,528,000Source | -179,817,000Source | -229,378,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 24,000Source | 833,000Source | 1,607,000Source | 1,832,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 10,555,000Source | 20,619,000Source | 28,518,000Source | 42,553,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -2,747,000Source | -1,656,000Source | 3,990,000Source | -1,813,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -171,266,000Source | -3,468,000Source | -159,158,000Source | -187,032,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 156,358,000Source | 29,023,000Source | -110,970,000Source | -1,035,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 79,000Source | 0Source | 0Source | 410,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 6,425,000Source | -11,488,000Source | 190,154,000Source | 117,090,000Source |
| Repayments of Long-term DebtUSD | 0Source | 12,581,000Source | 11,613,000Source | 5,806,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -8,342,000Source | 13,965,000Source | -79,864,000Source | -71,494,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 37,732,000Source | 46,074,000Source | 32,109,000Source | 111,973,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 10,000,000Source | 10,561,000Source | 12,288,000Source | 12,712,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 10,555,000Source | 20,619,000Source | 28,518,000Source | 42,553,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 985,000Source | 1,086,000Source | 1,321,000Source | 1,163,000Source |
| DepreciationUSD | 0Source | 800,000Source | 1,600,000Source | 1,800,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | 0Source | -806,000Source | -726,000Source | 0Source |
| General and Administrative ExpenseUSD | 37,631,000Source | 36,133,000Source | 38,455,000Source | 47,609,000Source |
| Income Tax Expense (Benefit)USD | -88,000Source | 893,000Source | — | — |
| InterestExpenseNonoperatingUSD | 10,989,000Source | 11,517,000Source | — | — |
| Investment Income, InterestUSD | 1,970,000Source | 1,779,000Source | 1,997,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -170,370,000Source | -56,528,000Source | -179,817,000Source | -229,378,000Source |
| Nonoperating Income (Expense)USD | 270,000Source | 4,284,000Source | 3,942,000Source | — |
| Operating ExpensesUSD | 219,199,000Source | 174,620,000Source | 183,759,000Source | 218,593,000Source |
| Operating Lease, ExpenseUSD | — | — | 3,400,000Source | 3,300,000Source |
| Other Nonoperating Income (Expense)USD | 9,289,000Source | 14,022,000Source | 15,456,000Source | 1,512,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | 1,930,000Source | 0Source | 0Source | 1,736,000Source |
| Realized Investment Gains (Losses)USD | 5,000Source | — | — | 0Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 48,471,000Source | 114,701,000Source | — | — |
| Operating Income (Loss)USD | -170,728,000Source | -59,919,000Source | -183,759,000Source | -218,593,000Source |
| Other Nonoperating Income (Expense)USD | 9,289,000Source | 14,022,000Source | 15,456,000Source | 1,512,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -170,458,000Source | -55,635,000Source | -179,809,000Source | -229,370,000Source |
| Income Tax Expense (Benefit)USD | -88,000Source | 893,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -170,370,000Source | -56,528,000Source | -179,817,000Source | -229,378,000Source |
| Earnings Per Share, BasicUSD per share | -0.75Source | -0.25Source | -1.18Source | -2.71Source |
| Earnings Per Share, DilutedUSD per share | -0.75Source | -0.25Source | -1.18Source | -2.71Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 228,519,130Source | 226,228,016Source | 152,621,669Source | 84,574,869Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 228,519,130Source | 226,228,016Source | 152,621,669Source | 84,574,869Source |
| Interest Expense (non-operating)USD | 10,989,000Source | 11,517,000Source | — | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 37,631,000Source | 36,133,000Source | 38,455,000Source | 47,609,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -138,048,000Source | -32,178,000Source | -134,073,000Source | -175,777,000Source |
| Interest ExpenseUSD | — | — | 13,511,000Source | 13,880,000Source |
| Investment Income, InterestUSD | 1,970,000Source | 1,779,000Source | 1,997,000Source | — |
| Nonoperating Income (Expense)USD | 270,000Source | 4,284,000Source | 3,942,000Source | — |
| Operating ExpensesUSD | 219,199,000Source | 174,620,000Source | 183,759,000Source | 218,593,000Source |
| Operating Lease, ExpenseUSD | — | — | 3,400,000Source | 3,300,000Source |
| Realized Investment Gains (Losses)USD | 5,000Source | — | — | 0Source |
Filing attachments
ex41.htm · 8-K · 2026-08-21
EX-4.1 5 ex41.htm EX-4.1 Document Exhibit 4.1 THE OFFER AND SALE OF THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRE…
Read attachment ↗ex42.htm · 8-K · 2026-08-21
EX-4.2 6 ex42.htm EX-4.2 Document Exhibit 4.2 THE OFFER AND SALE OF THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRE…
Read attachment ↗ex43.htm · 8-K · 2026-08-21
EX-4.3 7 ex43.htm EX-4.3 Document Exhibit 4.3 THE OFFER AND SALE OF THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRE…
Read attachment ↗ex991.htm · 8-K · 2026-08-21
EX-99.1 10 ex991.htm EX-99.1 Document Exhibit 99.1 Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval - $150 Million of Committed Capital: $25 Million Funded Upfront at Initial Closing, Plus an Additional $125 Million that Funds Upon FDA Acceptance of the Seralutinib NDA in PAH - - Potential for Up to an Additional $100 Million Upon FDA Approval of Seralutinib - - Financi…
Read attachment ↗